Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for MNKD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 0.819M
March 31, 2026 -35.13M
December 31, 2025 246.88M
September 30, 2025 71.96M
June 30, 2025 -5.334M
March 31, 2025 1.59M
December 31, 2024 -86.78M
September 30, 2024 -2.263M
June 30, 2024 -44.45M
March 31, 2024 -3.373M
December 31, 2023 141.73M
September 30, 2023 -0.261M
June 30, 2023 -5.902M
March 31, 2023 1.226M
December 31, 2022 2.843M
September 30, 2022 19.53M
June 30, 2022 -1.776M
March 31, 2022 0.813M
December 31, 2021 97.37M
September 30, 2021 -0.59M
June 30, 2021 -51.49M
March 31, 2021 224.98M
December 31, 2020 18.69M
September 30, 2020 2.64M
June 30, 2020 28.19M
Date Value
March 31, 2020 0.331M
December 31, 2019 5.042M
September 30, 2019 65.50M
June 30, 2019 -0.676M
March 31, 2019 0.003M
December 31, 2018 35.97M
September 30, 2018 -1.823M
June 30, 2018 26.62M
March 31, 2018 0.528M
December 31, 2017 58.24M
September 30, 2017 -0.022M
June 30, 2017 15.42M
March 31, 2017 -0.075M
December 31, 2016 0.117M
September 30, 2016 -5.132M
June 30, 2016 47.59M
March 31, 2016 0.464M
December 31, 2015 49.84M
September 30, 2015 -53.21M
June 30, 2015 8.686M
March 31, 2015 1.186M
December 31, 2014 -1.667M
September 30, 2014 31.23M
June 30, 2014 37.13M
March 31, 2014 3.368M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 125.80M
ACADIA Pharmaceuticals, Inc. 10.49M
Gilead Sciences, Inc. 2.344B
Vertex Pharmaceuticals, Inc. -426.70M
Ocugen, Inc. 80.37M